Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease

por Cavalcante, Ludimila, Amin, Asim, Lutzky, Jose
Publicado 2015

Ipilimumab-induced thrombotic thrombocytopenic purpura (TTP)

por King, Jeanelle, de la Cruz, Javier, Lutzky, Jose
Publicado 2017

Recognising immunotherapy-induced meningoencephalitis: a case during treatment for primary metastatic melanoma of the bladder neck

por Grunhut, Joel, Brown, Shimron, Lutzky, Jose, Skoczylas, Leor
Publicado 2022

Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor

por Escandon, Julia, Peacock, Stephanie, Trabolsi, Asaad, Thomas, David B., Layka, Ayman, Lutzky, Jose
Publicado 2017

Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma

por Lutzky, Jose, Sullivan, Ryan J., Cohen, Justine V., Ren, Yixin, Li, Anlong, Haq, Rizwan
Publicado 2023

Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series

por Holbrook, Kourtney, Lutzky, Jose, Davies, Michael A., Davis, Jessica Michaud, Glitza, Isabella C., Amaria, Rodabe N., Diab, Adi, Patel, Sapna P., Amin, Asim, Tawbi, Hussein
Publicado 2019

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma

por Gibney, Geoffrey T., Hamid, Omid, Lutzky, Jose, Olszanski, Anthony J., Mitchell, Tara C., Gajewski, Thomas F., Chmielowski, Bartosz, Hanks, Brent A., Zhao, Yufan, Newton, Robert C., Maleski, Janet, Leopold, Lance, Weber, Jeffrey S.
Publicado 2019

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

por Clark, Joseph I., Singh, Jatinder, Ernstoff, Marc S., Lao, Christopher D., Flaherty, Lawrence E., Logan, Theodore F., Curti, Brendan, Agarwala, Sanjiv S., Taback, Bret, Cranmer, Lee, Lutzky, Jose, Luna, Theresa L., Aung, Sandra, Lawson, David H.
Publicado 2018

PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

por Ribas, Antoni, Algazi, Alain, Ascierto, Paolo A., Butler, Marcus O., Chandra, Sunandana, Gordon, Michael, Hernandez-Aya, Leonel, Lawrence, Donald, Lutzky, Jose, Miller, Wilson H., Campbell, Katie M., Delafont, Bruno, Marshall, Shannon, Mueller, Nancy, Robert, Caroline
Publicado 2020

Author Correction: PD-L1 blockade in combination with inhibition of MAPK oncogenic signaling in patients with advanced melanoma

por Ribas, Antoni, Algazi, Alain, Ascierto, Paolo A., Butler, Marcus O., Chandra, Sunandana, Gordon, Michael, Hernandez-Aya, Leonel, Lawrence, Donald, Lutzky, Jose, Miller, Wilson H., Campbell, Katie M., Delafont, Bruno, Marshall, Shannon, Mueller, Nancy, Robert, Caroline
Publicado 2021

A multi-center study of high dose Aldesleukin (Proleukin(® )(HD IL-2) + Vemurafenib Zelboraf(® )) therapy in patients with BRAF(V600 )mutation positive metastatic melanoma (procliv...

por Clark, Joseph, Flaherty, Lawrence, Ernstoff, Marc, Koon, Henry, Milhem, Mohammed, Militello, Gerald, Agarwala, Sanjiv, Curti, Brendan, Cranmer, Lee, Lao, Christopher D, Logan, Theodore F, Lutzky, Jose, Rudrapatna, Venkatesh, Daniels, Gregory, Taback, Bret, Aung, Sandra, Lowder, James, Lawson, David
Publicado 2014

Clinical activity of PD-1 inhibition in the treatment of locally advanced or metastatic basal cell carcinoma

por In, Gino Kim, Nallagangula, Aparna, Choi, Jacob Seung, Tachiki, Lisa, Blackburn, Matthew J, Capone, Stephen, Bollin, Kathryn B, Reuben, Daniel Y., Shirai, Keisuke, Zhang-Nunes, Sandy, Ragab, Omar, Terando, Alicia, Hu, Jenny C., Lee, Han, Bhatia, Shailender, Chandra, Sunandana, Lutzky, Jose, Gibney, Geoffrey Thomas
Publicado 2022

Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases

por In, Gino K., Ribeiro, Jennifer R., Yin, Jun, Xiu, Joanne, Bustos, Matias A., Ito, Fumito, Chow, Frances, Zada, Gabriel, Hwang, Lindsay, Salama, April K. S., Park, Soo J., Moser, Justin C., Darabi, Sourat, Domingo-Musibay, Evidio, Ascierto, Maria L., Margolin, Kim, Lutzky, Jose, Gibney, Geoffrey T., Atkins, Michael B., Izar, Benjamin, Hoon, Dave S. B., VanderWalde, Ari M.
Publicado 2023

Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy

por Khan, Shaheer, Lutzky, Jose, Shoushtari, Alexander N., Jeter, Joanne, Marr, Brian, Olencki, Thomas E., Cebulla, Colleen M., Abdel-Rahman, Mohamed, Harbour, J. William, Sender, Naomi, Nesson, Alexandra, Singh-Kandah, Shahnaz, Hernandez, Susana, King, Jeanelle, Katari, Manpreet S., Dimapanat, Lyssa, Izard, Stephanie, Ambrosini, Grazia, Surriga, Oliver, Rai, Alex J., Chiuzan, Codruta, Schwartz, Gary K., Carvajal, Richard D.
Publicado 2022

Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors

por Sanborn, Rachel E, Pishvaian, Michael J, Callahan, Margaret K, Weise, Amy, Sikic, Branimir I, Rahma, Osama, Cho, Daniel C, Rizvi, Naiyer A, Sznol, Mario, Lutzky, Jose, Bauman, Julie E, Bitting, Rhonda L, Starodub, Alexander, Jimeno, Antonio, Reardon, David A, Kaley, Thomas, Iwamoto, Fabio, Baehring, Joachim M, Subramaniam, Deepa S, Aragon-Ching, Jeanny B, Hawthorne, Thomas R, Rawls, Tracey, Yellin, Michael, Keler, Tibor
Publicado 2022

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival

por Mandalá, Mario, Larkin, James, Ascierto, Paolo A, Del Vecchio, Michele, Gogas, Helen, Cowey, C Lance, Arance, Ana, Dalle, Stéphane, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Marquez-Rodas, Ivan, Butler, Marcus O, Di Giacomo, Anna Maria, Lutzky, Jose, De La Cruz-Merino, Luis, Atkinson, Victoria, Arenberger, Petr, Hill, Andrew, Fecher, Leslie, Millward, Michael, Khushalani, Nikhil I, de Pril, Veerle, Lobo, Maurice, Weber, Jeffrey
Publicado 2021

Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma

por Sarnaik, Amod A., Hamid, Omid, Khushalani, Nikhil I., Lewis, Karl D., Medina, Theresa, Kluger, Harriet M., Thomas, Sajeve S., Domingo-Musibay, Evidio, Pavlick, Anna C., Whitman, Eric D., Martin-Algarra, Salvador, Corrie, Pippa, Curti, Brendan D., Oláh, Judit, Lutzky, Jose, Weber, Jeffrey S., Larkin, James M. G., Shi, Wen, Takamura, Toshimi, Jagasia, Madan, Qin, Harry, Wu, Xiao, Chartier, Cecile, Graf Finckenstein, Friedrich, Fardis, Maria, Kirkwood, John M., Chesney, Jason A.
Publicado 2021

An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0

por Sullivan, Ryan J., Atkins, Michael B., Kirkwood, John M., Agarwala, Sanjiv S., Clark, Joseph I., Ernstoff, Marc S., Fecher, Leslie, Gajewski, Thomas F., Gastman, Brian, Lawson, David H., Lutzky, Jose, McDermott, David F., Margolin, Kim A., Mehnert, Janice M., Pavlick, Anna C., Richards, Jon M., Rubin, Krista M., Sharfman, William, Silverstein, Steven, Slingluff, Craig L., Sondak, Vernon K., Tarhini, Ahmad A., Thompson, John A., Urba, Walter J., White, Richard L., Whitman, Eric D., Hodi, F. Stephen, Kaufman, Howard L.
Publicado 2018

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

por Larkin, James, Del Vecchio, Michele, Mandalá, Mario, Gogas, Helen, Arance Fernandez, Ana M., Dalle, Stéphane, Cowey, Charles Lance, Schenker, Michael, Grob, Jean-Jacques, Chiarion-Sileni, Vanna, Marquez-Rodas, Ivan, Butler, Marcus O., Di Giacomo, Anna Maria, Middleton, Mark R., Lutzky, Jose, de la Cruz-Merino, Luis, Arenberger, Petr, Atkinson, Victoria, Hill, Andrew G., Fecher, Leslie A., Millward, Michael, Nathan, Paul D., Khushalani, Nikhil I., Queirolo, Paola, Ritchings, Corey, Lobo, Maurice, Askelson, Margarita, Tang, Hao, Dolfi, Sonia, Ascierto, Paolo A., Weber, Jeffrey
Publicado 2023

Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-...

por Clark, Joseph I., Wong, Michael K.K., Kaufman, Howard L., Daniels, Gregory A., Morse, Michael A., McDermott, David F., Agarwala, Sanjiv S., Lewis, Lionel D., Stewart, John H., Vaishampayan, Ulka, Curti, Brendan, Gonzalez, René, Lutzky, Jose, Rudraptna, Venkatesh, Cranmer, Lee D., Jeter, Joanne M., Hauke, Ralph J., Miletello, Gerald, Milhem, Mohammed M., Amin, Asim, Richart, John M., Fishman, Mayer, Hallmeyer, Sigrun, Patel, Sapna P., Van Veldhuizen, Peter, Agarwal, Neeraj, Taback, Bret, Treisman, Jonathan S., Ernstoff, Marc S., Perritt, Jessica C., Hua, Hong, Rao, Tharak B., Dutcher, Janice P., Aung, Sandra
Publicado 2016